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Background: To compare the cost-effectiveness of treating early responders versus early 
nonresponders to an atypical antipsychotic (risperidone) and the cost-effectiveness of treating 
early nonresponders maintained on risperidone versus those switched to olanzapine.
Methods: This post hoc analysis used data from a randomized, double-blind, 12-week schizo-
phrenia study (Study Code: HGMN, n = 628). Participants were initially assigned to risperidone 
therapy. Early response was defined as a $ 20% improvement on the Positive and Negative 
Syndrome Scale (PANSS) total score from baseline to two weeks. Early responders continued 
on risperidone, whereas early nonresponders were randomized in a double-blind manner to con-
tinue on risperidone or switch to olanzapine for 10 additional weeks. Early responders and early 
nonresponders maintained on risperidone were compared for health-state utilities (benefits) and 
total cost over the 12-week study; early nonresponders maintained on risperidone or switched to 
olanzapine were compared from randomization (10-week period). Utilities were derived from 
the PANSS and adverse events. Mixed models were used to assess group differences in utilities. 
Treatment costs were calculated based on health states. Incremental cost-effectiveness ratios 
were then utilized to compare treatment groups.
Results: Early responders to risperidone had significantly greater total utility and lower total 
treatment costs than early nonresponders to risperidone. Compared with early nonresponders 
who continued on risperidone, those who were switched to olanzapine had significantly higher 
total utility scores at endpoint and numerically lower total treatment costs, reflecting significantly 
lower nonmedication treatment costs, even though medication costs were significantly higher 
compared with generic risperidone.
Conclusion: Treatment of early responders was more cost-effective than treatment of early 
nonresponders to atypical antipsychotic therapy. Switching early nonresponders to olanzapine 
resulted in improved treatment effectiveness, met the criteria for some dominance, and appeared 
modestly more cost-effective than maintaining treatment with generic risperidone.
Keywords: cost-benefit analysis, olanzapine, risperidone, treatment outcome, schizophrenia
Introduction
Before switching a patient with schizophrenia to a new antipsychotic medication, expert 
consensus guidelines recommend that clinicians wait 4–8 weeks before changing a 
patient’s antipsychotic regimen,1,2 in part due to the possibility of a delayed onset of 
action. However, a comprehensive meta-analysis and several post hoc analyses have 
tested and rejected the notion of a delayed response to antipsychotics.3–7
A number of studies have demonstrated that early nonresponse to antipsychotics 
is a strong predictor of subsequent nonresponse to continued treatment with the same 
antipsychotic. In one study, Correll et al found that every patient whose symptoms ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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had not improved by 20% after one week of treatment were 
not responders after four weeks.3 In a larger analysis, Kinon 
et al pooled five randomized, double-blind trials of antipsy-
chotics in the treatment of schizophrenia, and found that a 
lack of response at two weeks was a robust predictor of poor 
response at 12 weeks.4 These findings were extended in a 
naturalistic trial, where early nonresponders were found not 
only to have worse clinical outcomes, but worse functional 
and economic outcomes as well.5
All of these studies were retrospective in nature, but a 
recent 12-week clinical trial (HGMN)8,9 was specifically 
designed to examine the early response hypothesis in an 
a priori manner. This study confirmed previous clinical 
and functional findings demonstrating poor outcomes for 
individuals with schizophrenia who were not early respond-
ers to an atypical antipsychotic (risperidone). HGMN also 
examined whether early nonresponders who continue on the 
initial antipsychotic (risperidone) after the first two weeks 
of therapy differ in treatment outcomes from early nonre-
sponders who were randomized in a double-blind manner 
to another antipsychotic (olanzapine). Findings indicated 
that early nonresponders who switched to olanzapine had 
a small but significantly greater reduction in symptoms at 
endpoint relative to early nonresponders who remained on 
risperidone. However, the early responders to risperidone had 
significantly greater symptom reductions than either group 
of early nonresponders. The economic implications of these 
findings have not yet been studied.
The objectives for this analysis were two-fold: to compare 
the cost-effectiveness of treating early responders versus early 
nonresponders to an atypical antipsychotic (risperidone) over 
a 12-week period, and to compare the cost-effectiveness 
of treating early nonresponders to risperidone who were 
randomized in a double-blind manner to either continue on 
risperidone or to switch to olanzapine for an additional 10 
weeks of therapy.
Materials and methods
Data source
Data for this post hoc analysis came from a 12-week, ran-
domized, double-blind, flexible dose HGMN trial that was 
explicitly designed to validate whether early responders to 
risperidone had greater reductions in psychopathology rela-
tive to early nonresponders to risperidone, and secondly, to 
investigate the effects of switching early risperidone nonre-
sponders to olanzapine or continuing them on risperidone.8 
HGMN included adult patients aged 18–65 years who met the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV)10 criteria for schizophrenia, schizoaffective 
disorder, or schizophreniform disorder. The multicenter trial 
started in May 2006, ended in December 2007, and was con-
ducted at 64 centers in three countries. Before undergoing any 
study procedure, the eligible patients were given a complete 
description of the study and provided written informed consent. 
The study was conducted in accordance with the Declaration 
of Helsinki and was approved by the Ethics Committee from 
each participating institution. The clinical trial was registered 
with ClinicalTrials.gov (identifier NCT00337662).
During the 2–5-day initial screening period (study period 
1), study participants were assessed to ensure that they met 
the inclusion and exclusion criteria. Beyond age and diag-
nosis, the primary inclusion criteria included a score $ 45 
on the Brief Psychiatric Rating Scale (BPRS),11 total score 
extracted from the Positive and Negative Syndrome Scale 
(PANSS)12 a score of $4 (moderate) on at least two BPRS 
items: conceptual disorganization, suspiciousness, halluci-
natory behavior, and unusual thought content, a minimum 
Clinical Global Impressions-Severity scale13 rating of 4 (mod-
erately ill), and, within two weeks of the first visit, patients 
needed to have experienced an exacerbation of their illness 
that required an increased level of psychiatric care. Patients 
for whom risperidone or olanzapine was contraindicated, and 
those who had been hospitalized for more than two weeks 
preceding the first visit or had another serious or unstable 
medical condition were excluded.
During study period 2, patients began flexible dose therapy 
with risperidone 2–6 mg/day. Previous antipsychotic medica-
tions were discontinued abruptly, and risperidone was initiated 
with a dosing schedule of 2 mg/day on day 1, 4 mg/day on 
days 2–7, and flexible dosing 2–6 mg/day after day 7.
At week 2, patients who met the a priori definition for 
early nonresponse (,20% improvement on PANSS total 
score) were randomized to either continue with risperidone 
treatment 2–6 mg/day or switch to olanzapine 10–20 mg/day 
for the next 10 weeks. During this third study period, the use 
of   benzodiazepine/hypnotics/anxiolytics was permitted for 
the treatment of anxiety or insomnia as clinically indicated. 
In addition, patients who had been receiving a stable dose 
of an antidepressant or mood stabilizer for $30 days prior 
to the initiation of the study could continue on these medica-
tions at a stable dose. Further details of the parent trial are 
available elsewhere.8
Figure 1 gives a graphical depiction of the study design. 
The three study cohorts included the early responders (n = 144) 
and the two groups of early nonresponders (n = 378) who were 
randomized to either continue risperidone (ENR-RIS, n = 192) ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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or switch to olanzapine (ENR-OLZ, n = 186). Comparisons 
between early responders and early nonresponders contrasted 
only the individuals who were treated with risperidone over 
the 12 weeks of study periods 2 and 3, and the patients ran-
domized to olanzapine were excluded from this comparison. 
Comparison between the ENR-RIS and ENR-OLZ cohorts 
were evaluated only over the 10 weeks of study period 3.
Approximately 17% (106/628) of enrolled patients 
discontinued risperidone treatment before the end of study 
period 2. Of the 522 patients who completed the initial two 
weeks of risperidone treatment (study period 2), 72.4% were 
classified as early nonresponders, and 27.6% were classified 
as early responders. A similar portion of patients in each of 
the three cohorts discontinued study period 3: 30.6% of the 
early responder group, 30.2% of the ENR–RIS group, and 
32.3% of the ENR–OLZ group.8
Cost-effectiveness analysis
The US Public Health Service Task Force on   Cost-Effectiveness 
in Health and Medicine has recommended evaluating   different 
health states based on quality-adjusted life year (QALY) ratings, 
where a year of life is rated on a scale from 0 (worst possible 
health) to 1 (perfect health), as evaluated by members of the 
general public.14 The ratings at specific points in time are known 
as utilities. QALYs are calculated from utilities by weighting 
the utilities according to time spent (years) at each health state 
and summing across the full time period. In this analysis, the 
timeframe was limited to the 12-week study period.
The methods used for this cost-utility analysis mirrored 
those from a previously published study.15 In the current 
analysis, we used disease-specific utility weights for eight 
health states (based on PANSS scores) identified in previ-
ously published research.16,17 Lenert et al identified positive, 
negative, and cognitive symptoms through factor analysis, 
and then used cluster analysis to identify eight health states 
from the symptom factors. Using a standard gamble meth-
odology, utility scores were identified for the eight health 
states and ranged from 0.42 to 0.88 (see Table 1). In addition, 
Lenert et al developed disutilities for five common adverse 
events, ie, weight gain (0.959), orthostatic hypotension 
Study
period I
Screen
period
ENR
ER
(1) Olanzapine 10–20 mg/day
(1) Risperidone 2–6 mg/day
Double-blinded therapy period
Risperidone 2–6 mg/day
Study period II Study period III
Risperidone
2–6 mg/day
2–5 days 1 week 1 week 1 week 1 week 2 weeks2  weeks4  weeks
10 weeks
V1 V2
Randomization
Risperidone early responder (ER) Risperidone early non-responder (ENR)
V3 V4 V5 V6 V7 V8 V9
Figure 1 hgMn study design.
Notes: in the parent study, 522 individuals completed two weeks of risperidone treatment (study period 2), of whom 144 were classified as early responders and 378 were 
classified as early nonresponders. At visit 4, the 378 early nonresponders were randomized in a 1:1 fashion to continue treatment with risperidone (ENR-RIS; n = 192) or 
switch treatment to olanzapine (ENR-OLZ; n = 186). 
Abbreviations: mg, milligrams; V, visit; ENR-RIS, early nonresponders to risperidone randomized to continue treatment with risperidone; ENR-OLZ, early nonresponders 
to risperidone randomized to switch to olanzapine.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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(0.912), akathisia (0.898), pseudoparkinsonism (0.888), and 
tardive dyskinesia (0.857). At each assessment, a patient’s 
total utility was assessed using the multiplicative calculation 
of total utility = (PANSS health state utility) × (weight gain 
disutility) × (orthostatic hypotension disutility) × (akathisia 
disutility) × (pseudoparkinsonism disutility) × (tardive dyski-
nesia disutility).16 Instances of adverse events were identified 
from spontaneously reported adverse events or prespecified 
definitions from the clinical trial protocol.8 Weight gain was 
identified by a $ 7% increase in baseline body weight, ortho-
static hypotension by changes in supine to standing blood 
pressure and pulse, pseudoparkinsonism by the Simpson–
Angus Scale18 or anticholinergic medication use, akathisia 
by the Barnes Akathisia Scale,19 and tardive dyskinesia by 
the Abnormal Involuntary Movement Scale.20 Once a patient 
reported an adverse event in the post-treatment period, it was 
assumed to continue for the remainder of the study period.
Building on these PANSS-based health states further, 
Mohr et al21 estimated monthly treatment costs for the eight 
different health states in 1997 US dollars using data from a 
naturalistic cost and outcomes trial.22 We updated these costs 
to 2008 US dollars using the medical portion of the consumer 
price index (see Table 1). The medication acquisition cost 
of olanzapine and risperidone were estimated using the least 
expensive combination of average wholesale price doses.23 
To reflect the discounts and rebates affecting patients whose 
medication costs would have been paid by Medicaid, average 
wholesale price was further discounted by 25%.24 Total cost 
was estimated as the sum of inflation-adjusted monthly cost 
for the different health states (nonmedication cost) and study 
drug acquisition costs (medication cost).
The incremental cost-effectiveness ratio identifies 
the cost in dollars for each unit of increase effective-
ness gained. The cost per QALY gained is an important 
standard in cost-effectiveness research. The incremental 
cost-effectiveness ratio was to be calculated if one treatment 
was both more expensive and more effective. Alternatively, if 
one treatment was both more effective and less costly, it would 
be considered the dominant treatment, and an incremental 
cost-effectiveness ratio would not be calculated.
statistical methods
Analysis of baseline characteristics, utilities, costs, and 
cost-effectiveness were performed for both of the group 
comparisons of interest, ie, risperidone early responders 
versus risperidone early nonresponders (excluding patients 
randomized to olanzapine) and early nonresponders ran-
domized to continue with risperidone (ENR-RIS) versus 
switch to olanzapine (ENR-OLZ). Baseline characteristics 
were compared using t-tests for continuous variables and 
Chi-square tests for categorical variables. The mixed model 
for repeated measures was used to compare the total utility 
difference between treatment groups over time. The mixed 
model for repeated measures included a priori selected cova-
riates for gender, race, diagnosis type, age at illness onset, 
investigator, as well as baseline PANSS positive, negative, 
and cognitive scores, and baseline utility category. Reported 
values represent the predicted mean values (ie, SAS least 
squares means) after adjusting for these covariates.
Monthly treatment costs were summed across the study 
period, with missing values imputed using the last observa-
tion carried forward method. Only patients with complete 
baseline covariate information and at least one post-baseline 
outcome measure were included in the analytical sample. 
A propensity score was calculated using logistic regression 
with the a priori selected covariates from the mixed model 
for repeated measures. An analysis of covariance adjusting 
for the propensity score was used to compare the total cost, 
Table 1 Health state definitions
Disease state PANSS factora,b Severityb Dominant symptoms Utility Cost/month (2008)c
Negative Positive Cognitive
1 ,2.1 ,2.7 ,2.9 Mild 0.88 $2359
2 2.1–3.4 ,2.7 ,2.9 Moderate negative 0.75 $3323
3 ,3.4 ,3.9 ,2.9 Moderate Positive and negative 0.74 $5603
4 .3.4 ,3.9 ,2.9 severe negative 0.63 $6556
5 ,3.4 ,2.7 .2.9 severe Positive and cognitive 0.65 $7171
6 .3.4 ,3.4 .2.9 severe negative and cognitive 0.53 $7296
7 ,3.4 .3.9 severe Positive 0.62 $8182
8 .3.4 .3.9 Extremely severe 0.42 $9951
Note: aMean of pertinent items on a 0–6 scale; bfrom Lenert et al17; cupdated from 1997 to 2008 Us dollars using the medical component of the consumer price index (ratio 
of 384.943/239.1 = 1.610). 
Abbreviation: PAnss, Positive and negative syndrome scale.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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nonmedication cost, and medication cost of the two treatment 
groups. Due to the skew in the cost data, a sensitivity analy-
sis was conducted assessing mean cost differences using a 
propensity-score stratified, bootstrap resampling approach.25 
The bootstrap resampling provides for a test of mean cost dif-
ferences without making strong distributional assumptions, 
while the propensity stratification incorporates adjustment 
for the a priori set of baseline covariates.
Cost effectiveness was assessed based on the incremen-
tal cost-effectiveness ratio, defined as the group difference 
in mean costs divided by the group difference in utility. 
The variability of the incremental cost-effectiveness ratio 
estimate was generated by bootstrap resampling (5000 
iterations) of the cost and utility values simultaneously and 
examining the bootstrap distribution over the quadrants of 
the   cost-effectiveness plane. The degree of dominance cri-
teria26 was then used to judge the strength of the observed 
incremental cost-effectiveness ratio. According to these cri-
teria, if 95% of the bootstrap distribution of the incremental 
  cost-effectiveness ratio is in the dominant quadrant (more 
effective and less costly), then “strict” dominance has been 
obtained. Alternatively, if only 50% of the bootstrap distri-
bution of the incremental cost-effectiveness ratio is in the 
dominant quadrant (more effective and less costly), but 90% 
is in the three more effective or less costly quadrants, then the 
lesser criteria of “some” dominance has been obtained. All 
data analyses were completed using SAS version 9.1.3.
Results
The results are reported in two subsections reflecting parallel 
comparisons underlying the stated objectives: risperidone 
early responders versus risperidone early nonresponders and 
early nonresponders randomized to continue with risperidone 
(ENR-RIS) versus switch to olanzapine (ENR-OLZ). In the 
tables and figures, the results are juxtaposed to aid in con-
trasting the results from the two analyses.
Early responders versus early  
nonresponders to risperidone
This first analysis contrasts those who had an early response 
to risperidone (n = 139) versus those who did not have an 
early response to risperidone and were randomized to con-
tinue treatment with risperidone (n = 188). In Table 2, it 
can be seen that the population had an average age in their 
early 40s, average onset of illness in their mid-20s, most 
were male, the majority were either Caucasian or African-
American, and, on average, they had more severe positive 
than negative or cognitive symptoms of schizophrenia. At the 
beginning of treatment with risperidone, the early respond-
ers had significantly higher levels of positive symptoms and 
lower total utility scores than early nonresponders.
Total utility scores separated significantly between the 
early nonresponder and early responder groups at week 1 
and remained significantly different across the treatment 
period (see Figure 2A). On average, the total utility score 
was 0.835 for the early responder group and 0.780 for the 
early nonresponder group (P , 0.001). Although only for a 
period of 12 weeks, this difference represents a gain of 4.6 
quality-adjusted life days or 0.013 QALYs.
Over the 12-week study period (study periods 2 and 3), 
the estimated mean total cost of treating early nonresponders 
was significantly higher than for treating early responders 
Table 2 Baseline characteristics of patients
Variable ER-RIS  
(n = 139)
ENR-RIS  
(n = 188)
ENR-OLZa  
(n = 179)
ENR-RISa 
(n = 188)
Age, mean (sD) 42.1 (10.9) 41.9 (11.3) 42.0 (11.0) 42.0 (11.3)
Age at onset, mean (sD) 26.3 (10.7) 25.7 (10.2) 24.5 (8.8) 25.7 (10.2)
Race
  African-American, % (n) 37.4% (52) 47.3% (89) 46.4% (83) 47.3% (89)
  Caucasian, % (n) 51.8% (72) 42.6% (80) 43.6% (78) 42.6% (80)
  Other, % (n) 10.8% (15) 10.1% (19) 10.0% (18) 10.1% (19)
gender: Male, % (n) 59.7% (83) 59.6% (112) 64.8% (116) 59.6% (112)
PAnss total, mean (sD) 63.8 (14.3) 61.1 (12.9) 55.0 (13.8) 54.0 (14.9)
Utility total score, mean (sD)  0.74 (0.07)* 0.76 (0.10)* 0.78 (0.09) 0.77 (0.10 )
PAnss subscales16
  Positive, mean (sD) 3.1 (0.64)* 2.7 (0.64)* 2.4 (0.74) 2.3 (0.79)
  negative, mean (sD) 2.2 (0.74) 2.1 (0.86) 1.9 (0.74) 2.0 (0.83)
  Cognitive, mean (sD) 1.9 (0.58) 1.9 (0.74) 1.8 (0.63) 1.7 (0.70)
Note: *P , 0.05; aBaseline for the ENR-OLZ and ENR-RIS comparison was at the time or randomization (week 2 of treatment). 
Abbreviations: ER-RIS, early responder to risperidone; ENR-RIS, early nonresponder to risperidone randomized to continue treatment with risperidone; ENR-OLZ, early 
nonresponder to risperidone randomized to switch to olanzapine; SD, standard deviation; PANSS, Positive and Negative Syndrome Scale.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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($9951 ± $3626 versus $7974 ± $1886; difference = $1977, 
P , 0.001). The differences were driven primarily by non-
medication costs ($9528 ± $3610 versus $7560 ± $1864; 
difference = $1969, P , 0.001), with study medication costs 
not differing significantly between the early nonresponder 
and early responder groups ($422 ± $86 versus $414 ± $100; 
difference = $8, P = 0.278).
The early responders had significantly greater improve-
ments in total utilities and significantly lower total treat-
ment costs, resulting in early response being considered 
dominant. Figure 3A gives the bootstrap estimates of both 
the total utility changes and total cost changes. With nearly 
every estimate falling within the southeast quadrant, this 
clearly fits the definition of strict dominance (at least 95% 
of estimates falling in the more effective and less costly 
quadrant).26
Early nonresponders randomized  
to EnR-Ris or EnR-OLZ
This second analysis was a randomized comparison. In Table 2 
it can be seen that, at the time of randomization, the ENR-
RIS and ENR-OLZ groups had similar characteristics. At 
endpoint, total utility scores were higher for the ENR-OLZ 
group than for the ENR-RIS group (P = 0.029, see Figure 2B). 
The average total utility score for study period 3 was 0.808 
for the ENR-OLZ group and 0.799 for the ENR-RIS group 
(P = 0.197). This difference represents a gain of 0.6 quality 
adjusted life days over the 10-week period of study 3.
The total cost was not significantly different for the ENR-
RIS and ENR-OLZ treatment groups ($7989 ± $3058 versus 
$7875 ± $3244; difference = $114, P . 0.05) over study 
period 3. However, the nonmedication costs ($7621 ± $3044 
versus $6634 ± $3233; difference = $987, P , 0.001) 
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Figure 2 Total utility change over time. A) early responders versus early nonresponders over study periods 2 and 3. B) EnR-Ris versus EnR-OLZ over study period 3. 
Utility scores vary from 0 (death) to 1 (perfect health). The y-axis is restricted in range from 0.72 to 0.85 to highlight the pattern of change over time. 
Note: *P , 0.05. 
Abbreviations: ENR-RIS, early nonresponders to risperidone randomized to continue treatment with risperidone; ENR-OLZ, early nonresponders to risperidone 
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were significantly lower for the ENR-OLZ group, but were 
largely offset by a significantly higher study medication 
cost ($368 ± $81 versus $1241 ± $253; difference = $873, 
P # 0.001) for patients treated with olanzapine relative to 
those treated with generic risperidone.
Although the point estimate for the incremental 
cost-effectiveness ratio between the ENR-RIS and ENR-OLZ 
groups fell in the dominant quadrant (greater effectiveness 
and lower cost), the variability of this estimate did not meet 
the definition of strict dominance. In Figure 3B, it can be 
seen that the criteria of Obenchain et al for some dominance 
is met, given that .50% of the estimates fall in the dominant 
quadrant and .90% fall in the three more effective or less 
costly quadrants.26
Discussion
In this cost-effectiveness analysis, the treatment of early 
responders was found to be more cost-effective than the treat-
ment of early nonresponders. The treatment of patients who 
were early responders to risperidone was associated with a cost 
saving of nearly $2000 per patient over the 12-week period as 
compared with the treatment of patients who were early nonre-
sponders to risperidone. In addition, differences in total utility 
scores between early responders and early nonresponders to 
risperidone were significantly different by week 1, and the 
difference continued over the full 12-week treatment period. 
Using only the 12-week study period as the timeframe resulted 
in 0.013 QALYs gained (out of a possible 0.23 for 12 weeks). In 
cost-effectiveness vernacular, the early responder is considered 
a dominant choice over the early nonresponder but, beyond 
clinical acumen for matching patients with treatments, a clini-
cian cannot choose which individuals will be early responders 
to a specific antipsychotic medication.
The findings also suggest that switching the antipsychotic 
for early nonresponders from risperidone to olanzapine after 
only two weeks of treatment may represent a cost-effective 
treatment strategy. Early nonresponders to risperidone who 
were switched to olanzapine had better total utility scores after 
10 weeks of treatment (at endpoint). A significant reduction 
in nonmedication health care costs was offset by the higher 
medication acquisition cost of olanzapine relative to generic 
risperidone. The QALYs gained during the 10-week period 
were quite small, representing only 0.6 of a quality-adjusted 
life day per patient. In cost-effectiveness research, interpreting 
the dominance of a treatment when the point estimate is both 
more effective and less costly, but when only one (in this case 
the effectiveness) is statistically significant poses a challenge. 
Obenchain et al recommended considering the statistical 
significance of both the cost and effectiveness simultaneously 
and proposed three different levels of dominance.26 Our result, 
as displayed in Figure 3B, meets their criteria for the lowest 
level of dominance, ie, some dominance. Although not nearly 
as compelling as the results for the early responders relative 
to the early nonresponders to risperidone, switching patients 
who are early nonresponders to risperidone to treatment with 
olanzapine may represent a cost-effective strategy.
Our finding that early responders to atypical   antipsychotics 
had better outcomes in terms of QALYs is consistent with the find-
ings of other schizophrenia studies contrasting early responders 
and early nonresponders to various antipsychotic medications. 
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Figure 3 Distribution of 5000 bootstrap estimates of the incremental cost and 
effectiveness. A) Early responders versus early nonresponders comparison met 
criteria for strict dominance (95% of the bootstrap distribution in the more effective 
and less costly quadrant) and B) EnR-OLZ versus EnR-Ris comparison met criteria 
for some dominance (50% of the bootstrap distribution in the dominant quadrant 
with 90% in the three more effective or less costly quadrants). 
Abbreviations:  ENR-RIS,  early  nonresponders  to  risperidone  randomized  to 
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Previous studies have shown the implications of poor early 
response, not only in terms of poor response of core symp-
toms of schizophrenia,3,4,6,7 but also in terms of reduced clini-
cian-assessed quality of life, clinician-assessed functioning, 
patient-reported well-being, clinician-assessed depression,9 
patient-reported functioning, and patients’ perceptions of 
medication benefits.5 Previous studies have also found that 
health care costs were just over $2000 higher during an 
eight-week period for early nonresponders relative to early 
responders,5 a finding that is very similar to the cost finding 
in the current analysis. This growing body of research ques-
tions the prior recommendation from consensus treatment 
guidelines to wait 4–8 weeks before changing antipsychotic 
regimens for individuals who do not show a minimal early 
response to the initial antipsychotic medication.
Given the broad array of differences in outcomes between 
early responders and early nonresponders, one of the sober-
ing findings in this study was the large percentage of early 
nonresponders (72%, 378/522). Although some of these early 
nonresponders do later respond to treatment, the majority 
(approximately 80%) do not adequately respond.4,8 In the 
HGMN primary analysis,8 as well as in this cost-effectiveness 
analysis, switching medication to olanzapine showed a small but 
statistically significant improvement in outcomes at endpoint 
relative to continuing on risperidone. However, the patients who 
were switched to the alternative therapy did not have outcomes 
that were nearly as favorable as those for the early responders. 
These early nonresponders may represent a more difficult-to-
treat population, but more research investigating these initial 
poor responders is needed.
Limitations
The current analysis was restricted to patients treated with 
risperidone (early responders and early nonresponders), with 
early nonresponders randomized in a double-blind manner to 
continue on risperidone or switch to olanzapine. Therefore, 
our results may not generalize to other combinations of 
antipsychotic medication switches.
The total utility scores used in this analysis were calculated 
from symptom scores and adjusted for adverse event disutilities. 
The total utility score represents a weighted measure of both the 
efficacy and adverse events of the different medications as rated 
by a representative sample of individuals in the US.16 QALYs 
have been recommended for use in   cost-effectiveness research 
with antipsychotics because they allow direct comparison of 
therapies across a number of domains and can be understood 
in terms of willingness to buy a unit for this outcome.27 An 
additional strength of the PANSS-based QALY ratings16,17 is 
that they were based on health domains that are specifically 
affected by psychotic illnesses and, therefore, may be more 
sensitive to important changes in symptoms of schizophrenia 
than generic measures of quality of life.27
Our simplifying assumption that once an adverse event 
occurred it did not resolve during the study may have served 
to underestimate the total utility slightly. However, given 
the short duration of the trial and the size of adverse event 
disutilities relative to the disease state utilities, we anticipate 
this assumption had a negligible effect on the final results.
A challenge in conducting cost-effectiveness research 
using multinational clinical trials is that the patterns of 
resource use and the cost of those resources vary greatly by 
geography. In some countries, psychiatric hospitalization 
is inexpensive relative to the cost of medications, whereas 
in the US, psychiatric hospitalization represents one of the 
most expensive aspects of care. However, the mean dura-
tion of psychiatric hospitalization in the US is relatively 
short compared with some countries (eg, Brazil and Japan). 
To circumvent this issue in our analysis, cost was assigned 
based on previously identified monthly costs in the US for 
the different health states,21 rather than direct collection of 
and costing of resource use, which was not included in the 
HGMN trial. Costing based on health states has been used 
previously15 and involves some additional assumptions, 
including that health states are the main driver of costs and 
that the previously identified costs for the health states gen-
eralize to this patient population.
Finally, although the statistical analysis was adjusted for 
several important baseline variables, the results of the com-
parison between early responders and early nonresponders to 
risperidone are still open to biases from other confounders not 
accounted for in the statistical model. The patients who were 
early responders to risperidone may have differed in other 
significant ways from those who were early nonresponders.
Conclusion
Treatment of early responders was significantly more cost-
effective than the treatment of early nonresponders to atypical 
antipsychotic therapy (risperidone). Early nonresponders to 
antipsychotic therapy, following only two weeks of treat-
ment, appear to represent a group of patients who are more 
challenging to treat and tend to incur greater health care 
costs. In this study, switching early nonresponders from 
  risperidone to olanzapine at two weeks provided significantly 
lower nonmedication health care costs, significantly higher 
medication costs, and modest improvements in utility scores. 
One potential approach to the cost-effective treatment of ClinicoEconomics and Outcomes Research
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early nonresponders may be to switch their medications after 
two weeks. Further research into the effectiveness of switch-
ing paradigms and alternative treatments is needed.
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